Finance

Lists
Why is ABT down 2.17%?
Dive Deeper
ABT:NYSE
Abbott Laboratories
$96.69
-2.17%
(-2.14) 1D
$97.60
+0.94% (+0.91)
Pre-market
Closed: Oct 1, 4:03:03 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ABT...
Open
$99.10
High
$99.44
Low
$96.54
Mkt. cap
167.31B
Avg. vol.
8.34M
Volume
5.27K
Dividend
2.61%
Quarterly dividend
$0.63
Ex-dividend date
Oct 15, 2026
P/E ratio
31.12
52-wk high
$135.36
52-wk low
$81.97
EPS
$3.11
Beta
0.59
Shares outstanding
1.73B
No. of employees
115K
Open
$99.10
High
$99.44
Low
$96.54
Mkt. cap
167.31B
Avg. vol.
8.34M
Volume
5.27K
Dividend
2.61%
Quarterly dividend
$0.63
Ex-dividend date
Oct 15, 2026
P/E ratio
31.12
52-wk high
$135.36
52-wk low
$81.97
EPS
$3.11
Beta
0.59
Shares outstanding
1.73B
No. of employees
115K
News stories
From web sources and news partners
Profile
Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company founded in Chicago with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices. Abbott operates in over 160 countries and sources from at least 62 suppliers worldwide. Abbott's products include Pedialyte, Similac, BinaxNOW, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT and MitraClip. The company is ranked 107th on the Fortune 500 and 144th on the Forbes Global 2000. Wikipedia
About Abbott Laboratories
CEORobert B. Ford
Employees115K
Founded1888
HeadquartersChicago, Illinois, United States
SectorMedical device
Websiteabbott.com
Analyst ratings
Based on 14 analysts giving stock ratings to ABT in the past 3 months
Strong buy
Buy
14
Hold
0
Sell
0
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for ABT in the last 3 months.
Highest
Current $96.69
$135.00 (+39.62%)
Average
$124.64 (+28.91%)
Lowest
$112.00 (+15.83%)
Analyst
Recommendation
Action
Price target
Projected
Date
Larry Biegelsen
Wells Fargo
Buy
Maintained
$112.00
+15.8%
09/29/2026
Josh Jennings
TD Cowen
Buy
Reiterated
$135.00
+39.6%
09/14/2026
Joanne Wuensch
Citi
Buy
Maintained
$125.00
+29.3%
09/10/2026
Robbie Marcus
J.P. Morgan
Buy
Maintained
-
-
09/01/2026
Adam Maeder
Piper Sandler
Buy
Maintained
$118.00
+22%
08/26/2026
Matthew Taylor
Jefferies
Buy
Reiterated
$135.00
+39.6%
08/21/2026
Marie Thibault
BTIG
Buy
Maintained
$134.00
+38.6%
08/20/2026
Travis Steed
Bank of America Securities
Buy
Maintained
$115.00
+18.9%
08/20/2026
Brandon Vazquez
William Blair
Buy
Maintained
-
-
08/21/2026
Michael Polark
Wolfe Research
Buy
Upgraded
$130.00
+34.5%
08/13/2026
Danielle Antalffy
UBS
Buy
Reiterated
$125.00
+29.3%
07/28/2026
Patrick Wood
UBS
Buy
Reiterated
$125.00
+29.3%
07/28/2026
Unknown Analyst
Jefferies
Buy
Reiterated
$135.00
+39.6%
07/17/2026
Shagun Singh Chadha
RBC Capital
Buy
Reiterated
$130.00
+34.5%
07/16/2026
Jayson Bedford
Raymond James
Buy
Maintained
-
-
07/17/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
$112.00
+15.8%
07/06/2026
David Rescott
Robert W. Baird
Buy
Initiated
$121.00
+25.1%
06/30/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
$110.00
+13.8%
06/29/2026
David Roman
Goldman Sachs
Buy
Maintained
$113.00
+16.9%
05/31/2026
Narumi Nakagiri
Daiwa
Hold
Downgraded
$92.00
-4.9%
04/21/2026
Anthony Petrone
Mizuho Securities
Hold
Maintained
$115.00
+18.9%
04/20/2026
Matt Miksic
Barclays
Buy
Reiterated
$143.00
+47.9%
04/20/2026
Suraj Kalia
Oppenheimer
Buy
Maintained
$115.00
+18.9%
04/17/2026
Bruce Jackson
Benchmark Co.
Buy
Maintained
$120.00
+24.1%
04/17/2026
Rick Wise
Stifel Nicolaus
Buy
Reiterated
$120.00
+24.1%
04/17/2026
Unknown Analyst
Goldman Sachs
Buy
Reiterated
$121.00
+25.1%
04/09/2026
Unknown Analyst
Erste Group
Hold
Maintained
-
-
04/01/2026
Last report
Jul 16, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$1.31 / $1.28
+2.61%beat
Revenue / Est. (USD)
12.59B / 12.52B
+0.61%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
11.37B
11.46B
11.16B
12.59B
Cost of goods sold
5.08B
4.91B
4.89B
5.32B
Cost of revenue
5.08B
4.91B
4.89B
5.32B
Research and development expenses
766.00M
720.00M
767.00M
892.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.90B
2.93B
3.58B
3.87B
Operating expense
4.09B
4.07B
4.77B
5.42B
Total operating expenses
9.16B
8.98B
9.66B
10.74B
Operating income
2.20B
2.48B
1.50B
1.85B
Other non operating income
2.00M
-15.00M
-
-25.00M
EBT including unusual items
2.18B
2.36B
1.45B
1.52B
EBT excluding unusual items
2.18B
2.44B
1.45B
1.52B
Income tax expense
536.00M
582.00M
372.00M
596.00M
Effective tax rate
24.59%
24.68%
25.67%
39.11%
Other operating expenses
-
-
-
-
Net income
1.64B
1.78B
1.08B
928.00M
Net profit margin
14.46%
15.50%
9.65%
7.37%
Earnings per share
1.30
1.50
1.15
1.31
Interest and investment income
77.00M
78.00M
106.00M
52.00M
Interest expense
-121.00M
-120.00M
-174.00M
-351.00M
Net interest expenses
-44.00M
-42.00M
-68.00M
-299.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
3.00B
3.27B
2.31B
2.91B
Gain or loss from assets sale
-
65.00M
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps